Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis

August 28, 2017 updated by: Jennifer Ruiz, DPT, Mount Sinai Rehabilitation Hospital
Upper extremity (UE) function is critical to maintaining independence. Better understanding of UE involvement in MS will provide necessary information to prioritize the design and selection of future interventions. The goal of the proposed project is to characterize UE involvement in a population of community-based persons with MS across the International Classification of Functioning, Disability & Health (ICF) domains and constructs.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

267

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Connecticut
      • Hartford, Connecticut, United States, 06112
        • Mandell Center for Multiple Sclerosis at the Mount Sinai Rehabilitation Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Persons with MS who receive care at the Mandell Center for Multiple Sclerosis.

Description

Inclusion Criteria:

  • Confirmed clinical Clinical diagnosis of MS
  • Receive MS care at the Mandell MS Center
  • Cognitively able to understand directions and complete protocol
  • Signed consent form approved by the Saint Francis Institutional Review Board
  • 18 years of age or older

Exclusion Criteria:

  • Unwilling or unable to complete assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
PwMS receiving care at the Mandell Center

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Prevalance of Impairment in the Upper Extremity
Time Frame: 3hours
3hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mount Sinai Rehabilitation Hospital

Collaborators

National Multiple Sclerosis Society

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2013

Primary Completion (Actual)

October 1, 2016

Study Completion (Actual)

October 1, 2016

Study Registration Dates

First Submitted

March 2, 2015

First Submitted That Met QC Criteria

March 19, 2015

First Posted (Estimate)

March 25, 2015

Study Record Updates

Last Update Posted (Actual)

August 30, 2017

Last Update Submitted That Met QC Criteria

August 28, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 13-12-002-E
  • RG 4815A2/2 (Other Grant/Funding Number: National Multiple Sclerosis Society)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe